Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Condition: Congenital Hyperinsulinism · Sponsor: Zealand Pharma
About this study
This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 (NCT04172441) or ZP4207-17109 (NCT03777176) (defined as lead-in trials). The primary objective is to evaluate the long-term safety of dasiglucagon administered as a subcutaneous (SC) infusion in children with CHI.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (10)
| Children's Hospital Colorado | Aurora, Colorado, United States | — |
| The Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | — |
| Cook Children's Endocrinology and Diabetes Clinic | Fort Worth, Texas, United States | — |
| University Hospital Düsseldorf, Department of Pediatrics | Düsseldorf, Germany | — |
| Otto von Guericke University Magdeburg, Department of Pediatrics | Magdeburg, Germany | — |
| Hadassah Medical Center | Jerusalem, Israel | — |
| NHS Greater Glasgow and Clyde | Glasgow, United Kingdom | — |
| Alder Hey Children's Hospital NHS Foundation Trust | Liverpool, United Kingdom | — |
| Great Ormond Street Hospital for Children NHS Foundation Trust | London, United Kingdom | — |
| Manchester University NHS Foundation Trust | Manchester, United Kingdom | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03941236